Home >

API

Active Pharmaceutical Ingredients (APIs) are combined with excipients (inactive substances) to make drugs. Here you will find content about the development, manufacturing, analysis and regulation of pharmaceutical APIs.

Articles

Excipient-based strategies to harness complex therapeutics

Though excipients are a necessary drug component that can often be taken for granted, the ever-changing pharma landscape is always pushing us to shift our perspectives.

Bridging the gap between R&D and GMP

Companies prioritizing optimized synthetic routes, stable API forms, and verified analytical tools set the stage for phase I clinical manufacturing success

Toward a collaborative pharma ecosystem

A new biomanufacturing era demands that suppliers and manufacturers partner to efficiently bring new therapies to market

Reevaluating pharma packaging priorities

Supply chain challenges and industry trends are spurring new business strategies

Enzymaster completes round-C financing geared towards expansion

German-based biocatalysis solution provider Enzymaster has recently completed a round-C fundraiser of more than $45 million.

News

Pfizer recalls blood pressure drug

Incyte investigates API issue with newly-approved eczema cream

Sandoz to expand API production in Austria and Spain

Sanofi unveils name for new API company

Government watchdog finds nothing amiss in Kodak deal

US blocks Kodak's API loan

Global Dose: Focus on India

The world's leader of generic drug production looks towards new horizons in pharma

Top pharma industry predictions for 2021

In many ways, the beginning of 2021 isn’t just one of the most welcome New Years of the modern era — it could also be a turning point between the pre-COVID and post-COVID worlds...

The case for nanoparticles

Leveraging new powder technologies to manufacture personalized medicines

Manufactured patriotism

The government wants to reshore generics, but the drug industry isn’t celebrating

Harnessing lab power on the pharma plant floor

Technologies accelerating the verification process for raw materials

Bring it home

Inside the movement to put generic drug production back on America's shores

The growing benefits to reshoring pharma operations

The need to explore the diversification of U.S. pharmaceutical supply chains and the feasibility of relocation has never been higher.

Kodak scores major loan to make generic APIs

Eastman Kodak Co., a long-time producer of photography-related products, has won a $765 million loan to manufacture generic drug APIs.

Massive pharma campus marketed to drugmakers looking to onshore production

A 433-acre campus once owned by Bristol Myers Squibb is now being marketing as the perfect location for pharma companies looking to expand their manufacturing footprint in the...

Cadila Pharma closes API plant after workers test positive for COVID-19

Cadila Pharmaceuticals, one of the largest privately held pharma companies in India, shut down its API manufacturing plant in Ahmedabad after 26 employees tested positive for ...

API